

DEFINITIONS

In this document, unless the context otherwise requires, the following terms and expressions shall have the meanings set out below. Certain other terms and expressions are explained in the section headed “Glossary of Technical Terms” in this document.

“Accountants’ Report”	the accountants’ report of our Company, the text of which is set out in Appendix I to this document
“affiliate(s)”	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“AFRC”	the Accounting and Financial Reporting Council of Hong Kong
“Articles” or “Articles of Association”	the articles of association of our Company adopted on February 10, 2026, with effect upon the [REDACTED] (as amended from time to time), a summary of which is set out in Appendix V to this document
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Audit Committee”	the audit committee of our Board
“Board” or “Board of Directors”	the board of Directors

[REDACTED]

“Business Day”	a day on which banks in Hong Kong are generally open for normal business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong
----------------	---

[REDACTED]

“Chengdu Immunofoco”	Chengdu Immunofoco Biotechnology Co., Ltd. (成都易慕峰生物科技有限公司), our wholly-owned subsidiary incorporated under the laws of PRC with limited liability on October 18, 2022
“China” or “PRC”	the People’s Republic of China, which only in the context of describing PRC rules, laws, regulations, regulatory authority, and any PRC entities or citizens under such rules, laws and regulations and other legal or tax matters in this document, excludes Taiwan, Hong Kong and the Macau Special Administrative Region of the People’s Republic of China

DEFINITIONS

“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company” or “our Company”	Shenzhen Immunofoco Biotechnology Co., Ltd. (深圳易慕峰生物科技股份有限公司), a company established under the laws of the PRC as a limited liability company on July 16, 2020 and converted into a joint stock company with limited liability in the PRC on January 22, 2026
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“connected transaction(s)”	has the meaning ascribed thereto under the Listing Rules
“controlling shareholder(s)”	has the meaning ascribed thereto under the Listing Rules
“core connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Core Product”	has the meaning ascribed to it under Chapter 18A of the Listing Rules, is the product for the purpose of satisfying the eligibility requirements under Chapter 18A of the Listing Rule and Chapter 2.3 of the Guide for New Listing Applicants, and in this context, refers to IMC002
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)” or “our Director(s)”	the director(s) of our Company
“Dr. Sun”	Dr. Minmin Sun (孫敏敏), our founder, chairperson of the Board, executive Director and chief executive officer
“EIT”	enterprise income tax
“EIT Law”	the PRC Enterprise Income Tax Law (《中華人民共和國企業所得稅法》)
“ESG”	environmental, social and governance
“Extreme Conditions”	extreme conditions caused by a super typhoon as announced by the government of Hong Kong
“FDA”	U.S. Food and Drug Administration

[REDACTED]

DEFINITIONS

“Frost & Sullivan” Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. (弗若斯特沙利文(北京)諮詢有限公司上海分公司), our industry consultant

“F&S Report” the industry report commissioned by our Company and independently prepared by Frost & Sullivan, a summary of which is set forth in the section headed “Industry Overview” in this document

[REDACTED]

“Group”, “our Group”, “we”, “us” or “our” our Company and all of its subsidiaries, or any one of them as the context may require

“Guangdong Bioshare” Guangdong Hengqin Bioshare Technology Co., Ltd. (廣東橫琴曦爾瑞科技有限公司), our wholly-owned subsidiary incorporated under the laws of PRC with limited liability on June 23, 2026

“Guangzhou Bioshare” Guangzhou Bioshare Technology Co., Ltd. (廣州曦爾瑞科技有限公司), our wholly-owned subsidiary incorporated under the laws of PRC with limited liability on November 2, 2023

“Guide for New Listing Applicants” the Guide for New Listing Applicants published by the Stock Exchange

“H Share(s)” overseas listed foreign ordinary share(s) in the share capital of our Company with a nominal value of RMB[REDACTED] each, which are to be [REDACTED] for and [REDACTED] in Hong Kong dollars and to be [REDACTED] on the Stock Exchange

[REDACTED]

“HK Immunofoco” Immunofoco Pharmaceutical Technology Limited, our wholly-owned subsidiary incorporated under the laws of Hong Kong with limited liability on November 23, 2023

[REDACTED]

DEFINITIONS

[REDACTED]

“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollars” or “HK\$”	Hong Kong dollars and cents, respectively, the lawful currency of Hong Kong

[REDACTED]

“Independent Third Party(ies)”	any person(s) or entity(ies) who/which is not a connected person of our Company within the meaning of the Listing Rules
--------------------------------	---

DEFINITIONS

[REDACTED]

“Latest Practicable Date” August 11, 2026, being the latest practicable date for the purpose of ascertaining certain information contained in this document prior to its publication

[REDACTED]

“Listing Committee” the listing committee of the Hong Kong Stock Exchange

[REDACTED]

“Listing Rules” the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time

“Main Board” the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with the GEM of the Hong Kong Stock Exchange

“MOF” Ministry of Finance of the PRC (中華人民共和國財政部)

“Nanjing Bioshare” Nanjing Bioshare Technology Co., Ltd. (南京曦爾瑞科技有
限公司), our wholly-owned subsidiary incorporated under
the laws of PRC with limited liability on April 14, 2022

DEFINITIONS

“NDRC”	the National Development and Reform Commission of the PRC (中華人民共和國國家發展和改革委員會)
“NHC”	the National Health Commission of the PRC (中華人民共和國國家衛生健康委員會)
“NMPA”	the National Medical Products Administration of the PRC (國家藥品監督管理局), the successor to the China Food and Drug Administration (國家食品藥品監督管理總局)
“Nomination Committee”	the nomination committee of our Board
“NPC”	the National People’s Congress of the PRC (中華人民共和國全國人民代表大會)

[REDACTED]

“Overseas Listing Trial Measures”	the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) promulgated by the CSRC on February 17, 2023
“PBOC”	the People’s Bank of China (中國人民銀行), the central bank of the PRC
“PRC Company Law”	the Company Law of the People’s Republic of China (《中華人民共和國公司法》)
“PRC Government”	the central government of the PRC and all governmental subdivisions (including provincial, municipal and other regional or local government entities) and instrumentalities thereof or, where the context requires, any of them

DEFINITIONS

“PRC Legal Adviser”	Zhong Lun Law Firm, the legal adviser of our Company as to the PRC laws
“PRC Securities Law”	the Securities Law of the PRC (《中華人民共和國證券法》), as amended, supplemented or otherwise modified from time to time
“[REDACTED] Equity Incentive Scheme”	the share awards scheme of our Company which was adopted in November 2025, a summary of the principal terms of which is set forth in the section headed “Statutory and General Information — Employee Share Incentive Schemes — B. [REDACTED] Equity Incentive Scheme” in Appendix VI to this document
“[REDACTED] Investment(s)”	the investment(s) in our Company undertaken by the [REDACTED] Investors, details of which are set out in the section headed “History, Development and Corporate Structure — [REDACTED] Investments ” in this document
“[REDACTED] Investor(s)”	the investor(s) of the [REDACTED] Investment(s)
“[REDACTED] Share Option Schemes”	the share option schemes of our Company which were adopted in January 2021, August 2022 and August 16, 2026, respectively, a summary of the principal terms of which is set forth in the section headed “Statutory and General Information — Employee Share Incentive Schemes — A. [REDACTED] Share Option Schemes” in Appendix VI to this document
[REDACTED]	
“Regulation S”	Regulation S under the U.S. Securities Act
“Remuneration Committee”	the remuneration committee of our Board
“Renminbi” or “RMB”	Renminbi, the lawful currency of the PRC
“SAFE”	the State Administration of Foreign Exchange of the PRC (中華人民共和國外匯管理局)
“Securities and Futures Commission” or “SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“SG Immunofoco”	Immunofoco Pharmaceutical Technology Private Limited, our wholly-owned subsidiary incorporated in Singapore with limited liability on December 12, 2023

DEFINITIONS

“Shanghai Haiyi”	Shanghai Haiyi Biotechnology Partnership (Limited Partnership) (上海海嶧生物科技合夥企業(有限合夥)), a limited partnership established under the laws of PRC on July 1, 2020, one of our Single Largest Group of Shareholders
“Shanghai Immunofoco”	Shanghai Immunofoco Pharmaceutical Research Co., Ltd. (上海易慕峰醫藥研究有限公司), our wholly-owned subsidiary incorporated under the laws of PRC with limited liability on January 10, 2022
“Shanghai Yimu”	Shanghai Yimu Biotechnology Partnership (Limited Partnership) (上海嶧慕生物科技合夥企業(有限合夥)), a limited partnership established under the laws of PRC on July 1, 2020, one of our Single Largest Group of Shareholders
“Shanghai Yizhong”	Shanghai Yizhong Biotechnology Partnership (Limited Partnership) (上海嶧眾生物科技合夥企業(有限合夥)), a limited partnership established under the laws of PRC on September 3, 2021, one of our Single Largest Group of Shareholders
“Share(s)”	ordinary share(s) in the capital of our Company with a nominal value of RMB0.20 each, including both Unlisted Shares and H Shares
“Shareholder(s)”	holder(s) of our Share(s)
“Single Largest Group of Shareholders”	comprises (i) Dr. Sun, (ii) Shanghai Haiyi, (iii) Shanghai Yizhong and (iv) Shanghai Yimu
“Sole Sponsor”, “[REDACTED]” and “[REDACTED]”	the sole sponsor, the [REDACTED] and the sole [REDACTED] of the [REDACTED] of the H Shares on the Hong Kong Stock Exchange as named in the section headed “Directors and Parties Involved in the [REDACTED]” in this document
“Sophisticated Investor(s)”	has the meaning ascribed to it under Chapter 2.3 of the Guide for New Listing Applicants
	[REDACTED]
“State Council”	the State Council of the PRC (中華人民共和國國務院)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited
“subsidiary(ies)”	has the meaning ascribed thereto under the Listing Rules
“substantial shareholder(s)”	has the meaning ascribed thereto under the Listing Rules

DEFINITIONS

“Suzhou Immunofoco”	Suzhou Immunofoco Biopharmaceutical Co., Ltd. (蘇州易慕峰生物製藥有限公司), our wholly-owned subsidiary incorporated under the laws of PRC with limited liability on September 19, 2025
“Takeovers Code”	the Code on Takeovers and Mergers and Share Buy-backs published by the SFC (as amended, supplemented or otherwise modified from time to time)
“Track Record Period”	the two years ended December 31, 2025 and the six months ended June 30, 2026
[REDACTED]	
“United States” or “U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“Unlisted Share(s)”	ordinary share(s) in the share capital of our Company, with a nominal value of RMB0.20 each, which are subscribed for in Renminbi
“U.S. dollars”, “US\$” or “USD”	United States dollars, the lawful currency of the United States
“U.S. Securities Act”	the U.S. Securities Act of 1933, as amended, supplemented or otherwise modified from time to time, and the rules and regulations promulgated thereunder
“Wuhan Bioshare”	Wuhan Bioshare Technology Co., Ltd. (武漢曦爾瑞科技有限公司), our wholly-owned subsidiary incorporated under the laws of PRC with limited liability on June 15, 2026
“2026 [REDACTED] Share Option Scheme”	the share option scheme adopted by our Company on August 16, 2026, the principal terms of which are set forth in the section headed “Statutory and General Information — Employee Share Incentive Schemes — A. [REDACTED] Share Option Schemes — 2026 [REDACTED] Share Option Scheme” in Appendix VI to this document
“%”	percent